Showing 7671-7680 of 9550 results for "".
- OLYMPIA 1: Nemolizumab Shows Improvements in Prurigo Nodularis Symptomshttps://practicaldermatology.com/news/olympia-1-nemolizumab-shows-improvements-prurigo-nodularis-symptoms/2468705/Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with moderate to severe prurigo nodularis (PN). Researchers for the OLYMPIA 1 trial evaluated the efficacy and safety of nemolizumab in 286
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- SDPA: Strategic Supplement Strategies for the Derm PAhttps://practicaldermatology.com/news/sdpa-strategic-supplement-strategies-derm-pa/2468638/Sara Wilchowski, DMSc, MPAS, PA-C, presented “Strategic Supplement Strategies for the Derm PA” at SDPA’s 22nd Annual Fall Dermatology Conference in Las Vegas. The lecture explored the role of nutraceuticals and alternative medicines in supporting patients in their overall wellness jour
- Xylazine Wounds: Chronicity Linked to Necrosishttps://practicaldermatology.com/news/xylazine-wounds-chronicity-linked-necrosis/2468631/Xylazine-associated wounds frequently present on extremities with necrotic wound beds and increase in severity with chronicity, according to a systematic case series published in JAMA Dermatology. The case series was conducted across three academic hospitals looking at clinical characteris
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro
- Rademikibart 'Could Be Incredibly Important for Type 2'https://practicaldermatology.com/news/rademikibart-could-be-incredibly-important-type-2/2468551/A second-generation IL-4Rα inhibitor known as rademikibart shows promise for further elevating the standard of care for type 2 inflammatory conditions in the future, Dr. Christopher Bunick said during a presentation at the 44th Annual Fall Clinical Dermatology Conference. Dr. Bunick showed
- Starton Secures New Patent for Transdermal Lenalidomide Deliveryhttps://practicaldermatology.com/news/starton-secures-new-patent-transdermal-lenalidomide-delivery/2468506/Starton Therapeutics announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its STAR-LLD transdermal drug delivery patent application, providing potential extended patent protection through 2040. According to a press release, the development broad
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Study: Roflumilast cream 0.15% Significantly Reduces Itch, Improves Quality of Lifehttps://practicaldermatology.com/news/study-roflumilast-cream-015-significantly-reduces-itch-improves-quality-life/2468468/New data show that ZORYVE® (Roflumilast) cream 0.15% rapidly alleviates symptoms of atopic dermatitis (AD) and significantly improves patient-reported outcomes, including daily activity, sleep, and emotional well-being, according to Arcutis. The manufacturer announced in a pres
- Systematic Review Explores Thiamidol’s Impact on Hyperpigmentationhttps://practicaldermatology.com/news/systematic-review-explores-thiamidols-impact-on-skin-discoloration/2468460/Data from a recent systematic review of 14 clinical studies shows topical isobutylamido thiazolyl resorcinol (ITR) provides statistically significant improvement in various types of hyperpigmentation, including melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced hyperpigmentation.<